LYVDELZI DIN 02561492
Status: Marketed
Holder: GILEAD SCIENCES CANADA INC
Molecule: SELADELPAR (SELADELPAR LYSINE)
Available to quote
Health Canada record
| Active ingredient(s) | SELADELPAR (SELADELPAR LYSINE) 10 MG |
|---|---|
| Dosage form | Capsule |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A05AX07 SELADELPAR |
| Original market date | 25-Nov-2025 |
| Current status date | 25-Nov-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Gilead Sciences Canada Inc — licence 101221, currently licensed, last inspection rating C (2022-09-20).
Canadian shortage reports
| Status | Reason | Estimated resolution | Tier | Updated |
|---|---|---|---|---|
| active | 300MG | Tier 3 Drug Shortages About & Resources | 2026-09-11 |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36189 | 2025-10-16 | New Drug Submission (NDS) |